Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	4.89M 4.23M 3.94M 3.63M 6.85M 465M 6.92M 46.35M 18.19M 232M 18.35M 17.94M 770M	P/E 2016	-0.72x	P/E 2017	-9.3x
Enterprise Value	12.8M 11.08M 10.33M 9.5M 17.94M 1.22B 18.14M 121M 47.66M 609M 48.07M 47.01M 2.02B	EV / Sales 2016	73.3x	EV / Sales 2017	7.27x
Free-Float	60.28%	Yield 2016 *	-	Yield 2017	-

20-06-29	Aradigm Corporation Went Out of Business	CI
20-06-12	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI
20-04-27	Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	CI
20-04-08	Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	CI
20-03-30	Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	CI
20-03-30	Motion for Asset Sale Approved for Aradigm Corporation	CI
20-03-09	Bidding Procedure Approved for Aradigm Corporation	CI
20-02-20	Motion for Asset Sale Filed by Aradigm Corporation	CI
20-02-20	Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	CI
19-11-05	Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI
19-10-30	Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	CI
19-10-21	Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	CI
19-07-19	Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI

20-06-15	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-06-04	ARADIGM CORP : Other Events (form 8-K)	AQ
20-04-30	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-04-13	ARADIGM CORP : Other Events (form 8-K)	AQ
20-04-06	Aradigm : Announces Sale of Assets to Grifols, S.A.	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARADIGM CORPORATION	+36.88%	+25.50%	-	-	702K
LONZA GROUP AG	+0.90%	-2.33%	+0.68%	+13.87%	48.57B
REVOLUTION MEDICINES, INC.	+1.98%	+9.05%	+413.94%	+532.17%	41.95B
IQVIA HOLDINGS INC.	+3.44%	-4.65%	+28.34%	+8.81%	38.85B
BEONE MEDICINES AG	+1.40%	+0.10%	+6.61%	+61.93%	37.24B
CELLTRION, INC.	+2.42%	+5.72%	+12.38%	+44.79%	30.67B
ASCENDIS PHARMA A/S	-0.16%	-3.11%	-	-	16.1B
MEDPACE HOLDINGS, INC.	+2.20%	+0.48%	+34.71%	+127.15%	16.41B
EUROFINS SCIENTIFIC SE	+1.25%	+1.52%	+4.62%	+18.26%	13.97B
ICON PUBLIC LIMITED COMPANY	+4.25%	-8.23%	-1.49%	-35.46%	12.62B
Average	+5.46%	-0.78%	+62.47%	+96.44%	28.48B
Weighted average by Cap.	+1.92%	-0.12%	+82.15%	+120.33%

	2016	2017
Net sales	195K 169K 157K 145K 273K 18.54M 276K 1.85M 726K 9.28M 732K 716K 30.73M	14.46M 12.53M 11.68M 10.74M 20.28M 1.38B 20.5M 137M 53.86M 688M 54.33M 53.13M 2.28B
Net income	-32.94M -28.53M -26.59M -24.46M -46.17M -3.13B -46.69M -312M -123M -1.57B -124M -121M -5.19B	-10.7M -9.27M -8.64M -7.95M -15.01M -1.02B -15.17M -102M -39.86M -509M -40.21M -39.32M -1.69B
Net Debt	-9.37M -8.12M -7.57M -6.96M -13.14M -891M -13.28M -88.92M -34.9M -446M -35.2M -34.42M -1.48B	7.91M 6.85M 6.39M 5.88M 11.09M 752M 11.22M 75.07M 29.47M 376M 29.72M 29.06M 1.25B

Aradigm Corporation Stock Nasdaq

Stocks

US0385054004

Biotechnology & Medical Research

Valuation: Aradigm Corporation

Latest news : Aradigm Corporation

Press Releases: Aradigm Corporation

Quotes and Performance

Other Biotechnology & Medical Research

Financials

Company Profile